Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The Medicines for the People Act establishes a new National Institute for Biomedical Research and Development within the National Institutes of Health to develop affordable drugs, devices, and biologics through full-cycle research from early development to FDA approval. The Institute would conduct research using NIH labs and private contractors, with the federal government owning all patents and intellectual property, which would be licensed to nonprofits and public entities at reduced or no cost, while for-profit companies face cost-plus pricing restrictions. The bill mandates strict transparency, requiring researchers to publicly share all clinical trial data, safety information, and cost details within one year of publication in accessible repositories. Oversight would come from a 15-member governing board including patient advocates and public health officials while excluding pharmaceutical industry leaders and lobbyists, and the bill authorizes $90 billion in funding through fiscal year 2027 with annual evaluations measuring drug approvals, clinical trials, patents, and cost savings.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.